Table 1.

Cytotoxicity of (–)-cryptanoside A (1)^a

compound	HT-29	MDA-MB-231	OVCAR3	OVCAR5	MDA-MB-435	FT-194
1	0.22 ± 0.23	0.50 ± 0.05	0.14 ± 0.05	0.44 ± 0.08	0.20 ± 0.12	1.1 ± 0.17
digoxin	0.28 ± 0.03b	0.31 ± 0.03b	0.10 ± 0.01b	NT c	0.17 ± 0.02b	0.16 ± 0.15
paclitaxeld	3.4 ± 0.1	3.8 ± 0.1	4.9 ± 0.1	7.3 ± 0.1	1.9 ± 0.1	NT c

^aIC₅₀ values are the concentration (μM) required for 50% inhibition of viability of the human HT-29 colon, MDA-MB-231 breast, OVCAR3 and OVCAR5 ovarian cancer and MDA-MB-435 melanoma and the FT194 benign/non-malignant human fallopian tube secretory epithelial cell lines for a given test compound with a 72 h treatment and were calculated using nonlinear regression analysis with measurements performed in triplicate and representative of three independent experiments.

^bData reported previously.²²

^cNT: Not tested.

^dPositive control (IC₅₀ nM).